A multi-center study on the regenerative effects of erythropoietin in burn and scalding injuries: study protocol for a randomized controlled trial

Christina Irene Günter1*, Augustinus Bader2, Ulf Dornseifer3, Silvia Egert15, Sebastian Dunda4, Gerrit Grieb4, Thomas Wolter4, Norbert Pallua4, Tobias von Wild5, Frank Siemers5, Peter Mailänder5, Oliver Thamm6, Carsten Ernert7, Michael Steen7, Reiner Sievers9, Bert Reichert9, Afshin Rahmanian-Schwarz9, Hans Schaller9, Bernd Hartmann10, Max Otte11, Victoria Kehl12, Christian Ohmann13, Wolfgang Jelkmann14 and Hans-Günther Machens1

Abstract

Background: Although it was initially assumed that erythropoietin (EPO) was a hormone that only affected erythropoiesis, it has now been proposed that EPO plays an additional key role in the regulation of acute and chronic tissue damage. Via the inhibition of inflammatory reactions and of apoptosis, stem cell recruitment, advancement of angiogenesis and growth factor release, EPO enhances healing and thus restitutio ad integrum after trauma. Human skin contains EPO receptors and is able to synthesize EPO. We therefore hypothesize that EPO is able to optimize wound healing in thermally injured patients.

Methods/Design: This is a large, prospective, randomized, double-blind, multi-center study, funded by the German Federal Ministry of Education and Research, and fully approved by the designated ethics committee. The trial, which is to investigate the effects of EPO in severely burned patients, is in its recruitment phase and is being carried out in 13 German burn care centers. A total of 150 patients are to be enrolled to receive study medication every other day for 21 days (EPO 150 IU/kg body weight or placebo). A follow-up of one year is planned. The primary endpoint of this study is the time until complete re-epithelialization of a defined skin graft donor site is reached. Furthermore, clinical parameters such as wound healing, scar formation (using the Vancouver scar scale), laboratory values, quality of life (SF-36), angiogenic effects, and gene- and protein-expression patterns are to be determined. The results will be carefully evaluated for gender differences.

Discussion: We are seeking new insights into the mechanisms of wound healing in thermally injured patients and more detailed information about the role EPO plays, specifically in these complex interactions. We additionally expect that the biomimetic effects of EPO will be useful in the treatment of acute thermal dermal injuries.

Trial registration: EudraCT Number: 2006-002886-38, Protocol Number: 0506, ISRCT Number: http://controlled-trials.com/ISRCTN95777824/ISRCTN95777824.

Keywords: Erythropoietin (EPO), Burns, Regenerative medicine, Wound healing, Clinical trial, Randomization
Background
Over the past few years, our understanding of erythropoietin (EPO) has changed significantly. Although it was initially assumed that EPO was a hormone affecting erythropoiesis only [1], it has now been discussed that EPO plays a key role in the repair of acute and chronic tissue damage. It has also been proposed that EPO has a significant anti-inflammatory effect, whereby the inflammatory response is part of the normal reaction of any organism to injury. Via the inhibition of inflammatory reactions, EPO influences healing and thus promotes *restitutio ad integrum* after trauma [2].

In addition, EPO seems to be involved in ensuring that stem cells are recruited to the required location. The best-known effect is the endothelial nitric oxide synthase (eNOS) mediated response and the recruitment of endothelial progenitor cells (EPCs) [3]. *In vitro* data show enhancement of stem cell proliferation and stem cell phenotype-conservation caused by EPO in human mesenchymal dermal stem cells grown under hypoxic conditions and in IL-6 enriched media [4].

Additionally, there are numerous publications reporting EPO’s function as a protective molecule of capillary endothelial cells, which under hypoxic stress would normally become apoptotic, thus improving the blood supply in the surrounding tissues [5]. In many tissues, inhibition of apoptosis is induced directly via a phosphorylation cascade initiated by the EPO receptor. Numerous pathways can be attributed to phosphorylation of janus kinase 2 (JAK-2) and subsequent phosphorylation of signal transducers and activators of transcription (STATs) and B-cell lymphoma extra-large (BCL-XL) or are mediated via phosphatidylinositol-3 kinase (protein kinase A) (PI3K-Akt) and mitogen-activated protein kinase (MAPK) pathways [6,7]. STAT then evokes apoptotic inhibition in the nucleus. Furthermore, Akt (protein kinase B) is activated, which plays a central role in cell survival [8].

Several authors report that EPO also triggers a variety of growth factors (see Table 1). Since we are focusing our discussion onto factors which are known to be involved in wound healing, the present work describes a selected number of growth factors and their effects.

Several publications indicate that the actions of specialized proinflammatory cells, such as leukocytes and macrophages, are down-regulated by EPO: the production of IL-2, IL-6, IL-8, γ-interferon and tumor necrosis factor α (TNF-α) is antagonized [10,14,25].

Normal human skin contains EPO receptors and is able to synthesize EPO. In culture, under hypoxic conditions, EPO synthesis increases [26].

In a mouse model the combined presence of EPO receptor (EPOR) and the EPO-hetero-receptor could be demonstrated in healthy and scalded skin. Additionally, after systemic EPO application the EPOR was significantly down-regulated in the healthy skin; by contrast, in the scalded skin, the expression rate stayed unchanged [27].

Several investigations on the effects of EPO on wound healing have shown predominantly elevated vascular endothelial growth factor (VEGF) and endothelial growth factor levels (and resulting elevated capillary density) in treatment groups compared to controls. This was emphasized by increased cluster of differentiation 31 (CD31) gene expression. Higher protein and collagen densities, as well as the greater mechanical stability of fresh cicatrices, were found in treatment groups as well [28].

One of the first research projects to examine the effects of EPO on wound healing, used fibrin-filled subcutaneously implanted chambers. These chambers were then injected with an EPO/fibrin mixture with different concentrations of EPO. The formation of granulation tissue was stimulated by the administration of EPO. When an anti-EPO or anti-EPO receptor antibody was added, the formation of granulation tissue deteriorated [29].

An *in vitro* study examined the effects of EPO and EPO receptors in human hair follicles. It was shown that hair follicle cells produce EPO and EPO receptors and that EPO shows its typical tissue-protective effects. Protective effects against chemotherapy-induced apoptosis of hair follicle cells was demonstrated [26]. Skin-derived EPO appears to act locally, while it is less important for the systemic EPO response to acute hypoxia in healthy humans [30].

The effects of subcutaneous EPO on dermal regeneration were also investigated using nude mice. In this model, the healing of a full thickness defect was traced directly into the skin-fold chamber in nude mice. It was shown that with EPO the healing process not only improved but was also accelerated depending on the dosage [31].

In another mouse model, after thermal trauma and subsequent EPO treatment, improved and accelerated wound healing was observed compared to the control group [32]. This was marked by increased epithelial proliferation, maturation of the extra-cellular matrix, increased angiogenesis and increased capillary density, identified by high CD31, VEGF values and eNOS activity. When mice were administered anti-EPO antibodies, wound healing deteriorated below that of the control group. After thermal trauma in mice and subsequent EPO treatment, mice exhibited improved and accelerated re-epithelialization as well as faster wound healing compared to control groups. This was characterized by increased epithelial proliferation, and maturation of extra-cellular matrices, as well as increased angiogenesis and capillary density detectable via high CD31 and VEGF values and eNOS activity [32].
The above findings lead to the assumption that EPO represents a new, effective therapeutic opportunity for the treatment of acute dermal thermal injuries.

### Methods/Design

This study is conducted according to globally accepted standards of good clinical practice (as defined in the ICH E6 Guideline for Good Clinical Practice, 1 May 1996), in agreement with the Declaration of Helsinki and in keeping with local regulations. It has full approval of the designated ethic committee (at the University of Lübeck, Ratzeburger Allee 160, Building 21, 23562 Lübeck, Germany) and is funded by the German Federal Ministry of Education and Research. Additionally, the study received support for medication costs from Heraeus Holding GmbH.

### Objectives

The study objectives are to demonstrate a cytoprotective and regenerative effect of erythropoietin in thermally injured patients in terms of reduced morbidity and mortality and to better understand the cellular mechanisms of erythropoietin in skin graft donor sites (SGDSs) and second-degree wounds (SDWs).

### Study design

This is a prospective, randomized, double-blind, multi-center clinical trial, conducted in 13 burn care centers in Germany. In total, 150 adult patients with burn and scald injuries will be included.

Via a centralized randomization list, patients are randomly allocated to the drug- or the placebo-treated group. Patients receive normal state-of-the-art burn care treatment plus study medication every other day. Study wound sites (SGDCs and SDWs) are treated with standard wound dressings. Dressing changes, wound documentation, photo documentation, biopsies, control of safety parameters, study medication and other relevant actions are strictly regulated in the study protocol. The acute treatment and observational phase is 28 days, with follow-up controls at Day 42, after 6 months and 12 months after inclusion.

### Table 1 Most important effects of EPO on different growth factors in wound healing

| Factor | Action | EPO action | Tissue, organ, species | Reference |
|--------|--------|------------|------------------------|-----------|
| TNF-α  | Primary-injury response | Antagonist | Neuronal tissue, brain, mice | [9] |
| IL-2,-6,-8 | Proinflammatory cytokines | Inhibition | Human histiocytic lymphoma cells | [10] |
| γ-interferon | Proinflammatory cytokine | Inhibition | Human histiocytic lymphoma cells | [10] |
| MIP 1 u. 2 | Proinflammatory protein | Inhibition | Cartilage, mice (arthritis model) | [12] |
| Myeloperoxidase | Invasion-marker for macrophages | Inhibition | Neuronal tissue, brain, mice | [13] |
| IL-1β | Proinflammatory cytokine | Inhibition | Human histiocytic lymphoma cells | [10] |
| γ-interferon | Proinflammatory cytokine | Inhibition | Human leucocytes | [14] |
| VEGF | Angiogenesis | Stimulation | Skin, microvessels, mice | [15] |
| eNOS | Recruitment of EPCs | Stimulation | Skin, microvessels, mice | [16] |
| EGF | Angiogenesis | Stimulation | Heart, microvessels, renovasculature, rat | [17] |
| HIF-1α / HIF-2α | Adaption to hypoxia, stimulation of EPO and VEGF | Stimulation | Human hepatoma cell lines | [18] |
| EPAS 1 | Adaption to hypoxia | Stimulation | Cortical astrocytes | [19] |
| INOS | Relaxation of smooth muscle cells | Stimulation | Skin, microvessels, mice | [15] |
| BCL-XI | Anti-apoptotic cell proliferation | Stimulation | Erythroid progenitor cell line, mice | [20] |
| IGF-I | Anti-apoptotic cell proliferation | Stimulation | Astrocytoma cell line | [21] |
| Caspase-3 | Apoptosis | Inhibition | Kidney, rat | [22] |
| BCL-2 | Anti-apoptotic cell proliferation | Stimulation | Erythroid progenitor cell line, mice | [23] |
| hsp 70 | Intracellular protective processes | Stimulation | Human TF-1 cell line | [24] |

BCL: B-cell lymphoma; EGF: endothelial growth factor; eNOS: endothelial nitric oxide synthase; EPAS: endothelial PAS domain-containing protein; EPC: endothelial progenitor cell; hsp: heat shock protein; IGF: insulin-like growth factor; INOS: inducible nitric oxide synthase; MIP: macrophage inflammatory protein; TNF: tumor necrosis factor; VEGF: vascular endothelial growth factor.
Patient population

Adult patients between 18 and 75 years of age with deep burns (deep second (2b) or third degree) or scalding injuries between 5% and 60% of total body surface (TBS) (patients under 40 can have more than a 60% TBS injury), and where a necrectomy and consecutive split skin graft transplantation is indicated, are to be included in the trial. Patients who are either pregnant or breastfeeding are to be excluded. Informed consent in written form must be given before the first study-specific action, by the patient, the patient’s legal representative or via the Heidelberger Verfahren. The Heidelberger Verfahren, first described by Brückner et al. [33], allows recruitment of patients who are unable to give informed consent themselves and where there is insufficient time to appoint a legal representative. In such cases, a judge, in consensus with the ethics committee and the judicial court, decides whether a patient can take part in the trial and gives the patient’s next-of-kin the authority to give informed consent on behalf of the patient. However, in cases where a next-of-kin is not available or unknown, the judge has the legal authority to give informed consent in advance and simultaneously a legal representative will be designated, who will subsequently give informed consent. Additionally as soon as the patient is able to give informed consent, he or she will be asked to do so.

Inclusion criteria

3° burn and scalding thermal injuries obligate, 2° burn and scalding thermal injuries optional, which require operations including split skin harvesting and grafting

Men and women, age ≥ 18 and ≤ 75 years

Secure contraception.

Exclusion criteria

Admission later than 24 hours after injury.

Hematological disorders (anemia, lymphoma, leukemia, inborn coagulation diseases).

Pregnancy or breast-feeding.

Estimated survival shorter than one week (abbreviated burn severity index (ABSI) > 12) in patients older than 40 years of age.

Body weight < 50 kg or > 110 kg

Total burn surface area involved less than 60% in patients older than 40 years of age.

In patients below 40 years of age no limitation of maximum burned body surface and no limitation of ABSI score will be considered.

Upper lateral thighs of both legs thermally injured.

Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.

Subject is unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.

Treatment with any investigational product in the last 12 months before study entry.

Treatment with any immunosuppressive therapy, cancer-related chemotherapy or radiation therapy in the past 12 months.

History of hypersensitivity to the investigational products.

Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.

Clinically relevant cardiovascular (s.p. cardiac infarction, coronary heart disease (CHD), treatment-resistant hypertension, thromboembolic disease, thromboembolic events shortly before admission), hepatic (Child B or C liver disease), endocrine (morbid obesity (BMI > 40)) or systemic (cancer) disease (malignoma).

EPILEPTIFORM diseases.

Phenylketonuria.

HIV disease, AIDS.

Informed consent missing.

Treatment

Randomized patients receive state-of-the-art burn care treatment including (depending on the clinical situation of the individual patient) analgosedation, respiration, escharectomy and split skin grafting or, if necessary, temporary wound closure. General wound care and wound dressings can be used, as they are standard practice in the study centers. The only exceptions are the studied split SGDS, the studied second-degree wound and the studied third-degree wound, which have to be treated as described in detail in the study protocol.

The study medication is either 150 IU recombinant human EPO (rhEPO) (NeoRecormon Multidose 50,000 IU, Roche, Grenzach-Wylen, Germany) per kilogram of body weight or a matched placebo (see Table 2), which is administered every other day subcutaneously for 21 days. The split SGDS is to be generated on Day 2 of study treatment and special wound dressings with a polyurethane foil have to be applied according to the trial protocol. Dressing changes and wound controls are

| Substance                  | Amount  |
|----------------------------|---------|
| NaCl                       | 8.24 g  |
| Benzyl alcohol             | 3.67 g  |
| Benzalkonium chloride      | 0.58 g  |
| H₂O ad injectionem        | Ad 1,000 ml |
made at specified time points. Patients receive a standard-
ized anticoagulant therapy with body weight-adjusted
intravenous heparin.

**Measurements**
Race, gender, age, height, weight, TBS burned percentage,
severity of burn (grades 1, 2a, 2b or 3), ABSI and concomi-
tant illnesses or injuries will be documented upon admis-
sion. Woman of reproductive age will undergo a pregnancy
test to check for an unknown pregnancy.

Daily controls of the organ failure parameters, using
the sequential organ failure assessment (SOFA), and safety
relevant parameters will be performed. The wound will be
clinically assessed and photographs taken according to the
protocol. Special EPO-related blood samples will be taken
once a week for four consecutive weeks. Punch biopsies
will be performed from the SGDS and the SDW four
times and once from healthy skin as a control.

**Primary endpoint**
The primary endpoint is the time until complete re-
epithelialization of the SGDS at a specified location on
the lateral upper thigh.

**Secondary endpoints**
Time until complete wound healing of type 2a SDW
- Time until complete wound healing of skin graft.
- Cellular and molecular regenerative effects in SGDS
  and type 2a SDW, Endothelial.

Progenitor Cell (EPC) recruitment, EPO receptor
up- or down-regulation, protein-, RNA- and microRNA-
expression patterns
- Quality of scar formation in conservatively and
  operatively treated wound locations.
- Number of packed red cells units, which are
  transfused during the treatment interval- Organ
dysfunction parameters- Quality of life 12 months
  after trauma (SF-36)- Mortality (within 21 days,
during the hospital stay and 1 year on).
- Adverse events (AEs), Serious Adverse Events
  (SAEs), Suspected Unexpected Serious.

Adverse Reactions (SUSARs)
- Gender differences in monitored data.

**Safety data**
The safety endpoints include AEs, SAEs, SUSARs, labora-
tory test results and vital signs. The data safety monitoring
board (DSMB) will supervise the occurrence of AEs, SAEs,
SUSARs and overall safety parameters.

A group of independent experts will form the Safety
Monitoring Board. The DSMB will independently review
the safety data for the duration of the study. In addition,
the coordinating investigator will inform the DSMB of
any SUSARs with a written report.

The DSMB will give advice when specific actions are
necessary. The study sites will be immediately informed
of the procedures. The DSMB will discontinue the study
if a quantitative accumulation of SAEs is observed. In
addition, if there is an unexpected accumulation of SAEs
other than mentioned above during the study, the
DSMB will discontinue the study. Additionally, annual
safety and progress reports have to be prepared for the
authorities and the independent ethics committees.

**Statistical considerations**

**Sample size justification**
Under conventional treatment, complete re-epithelialization
of split skin graft donor sites occurs after a mean of 10 to
15 days with a standard deviation (SD) of about 6 days,
depending on the donor site and the patient's general condi-
tion. We expect that EPO treatment can reduce the total
healing time by at least 4 days. Sample size calculation with
alpha = 0.05 and beta = 0.10 thus indicates that 48 evaluable
patients per group are necessary. In order to have 96
patients with valid data for the intention-to-treat analysis of
the primary outcome, we aim to include 150 patients. This
allows for 54 dropouts (34%).

**Statistical analysis**
Analyses will include all randomized patients with at
least one exposure to the study drug. In addition to the
intention-to-treat population, an exploratory analysis of all
patients completing the study as planned (per protocol
analysis) will be carried out. Standard statistical testing
will be used to examine the superiority of one treatment
arm. Testing will be adjusted for two stratification factors:
ABSI group and hospital. The primary endpoint for the
time taken for re-epithelialization of the skin graft donor
site will be analyzed as a continuous variable with normal
distribution. A safety analysis will be carried out for all
adverse events (regardless of severity). According to
current standards, the safety analysis will exclude those
patients who failed to receive any study drug dose. A list
of all adverse events will be provided and periodically
distributed to the DSMB. The two-sided significance level
for the final analysis is 0.05.

**Discussion**
The primary aim of this study is to evaluate the effect of
repetitive low dose rhEPO administered within 21 days
in severely thermally injured patients. There are several
reasons to believe that repetitive low dose rhEPO will
improve wound healing in this patient population
without severe adverse events or other grave complications. rhEPO is a well-known drug and has been used for nearly 30 years in daily clinical practice to treat anemia [34]. Thus the risk/benefit ratio for patients is relatively concrete to estimate, and will be discussed later. In addition the erythropoietic response to EPO is markedly decreased in thermally injured patients [35,36].

During the last two decades of the 20th century, scientific interest has turned towards treating burned patients with EPO, especially those patients who refuse blood transfusions and blood products due to religious reasons [35,36]. Several single-case reports have been published and two trials have been performed on thermally injured patients in intensive burn care units in an attempt to improve erythropoiesis. Both trials failed to show that doses between 300 and 500 IU rhEPO per kilogram of body weight daily for 7 days could significantly reduce the amount of required red blood cell transfusions. No statistically significant differences in hemoglobin, hematocrit, reticulocyte count, ferritin, serum iron, total iron binding capacity or transfusion requirements were found in either study. The effects on wound healing were not within the scope of the studies and therefore not monitored. In patients with burns involving 25% to 35% of total body surface, the reticulocyte counts were statistically significantly higher. In one trial it became evident that iron supplementation needs to be performed in patients receiving 500 IU EPO/kg body weight daily for 7 days to avoid iron depletion. In the other trial, three patients in the rhEPO group suffered venous thrombosis, compared with one patient in the placebo group. No further adverse side effects, possibly related to EPO, were encountered in either trial.

In 2005, an in vitro study showed that the serum of burned mice had elevated EPO levels, and bone marrow cell cultures treated with this serum reacted with increased proliferation rates [37].

The fact that no increase in hemoglobin, hematocrit, reticulocyte or erythrocyte count was found in either study is an especially interesting aspect regarding the treatment of burned patients; besides the well-known fact of decreased EPO efficacy regarding erythropoiesis in inflammation and in trauma situations of the organism, no explanation for this phenomenon has been given so far.

Known complications of EPO treatment are thromboembolic events. A large multi-center trial investigating the safety of EPO administration to poly-traumatized patients demonstrated EPO is safe and beneficial for these patients and that thromboembolic events were reduced to ranges seen in poly-traumatized patients not receiving EPO when combined with an appropriate anti-thrombotic therapy [38]. As the thromboembolic risk of thermally injured patients is comparable to that of poly-traumatized patients, we conclude that EPO administration in thermally injured patients is safe when combined with an adequate anti-thrombotic prophylaxis as it is done in our trial.

There are two further well-known adverse events related to EPO. The first is the increase in blood pressure in already hypertonic patients [39] with the consequence that therapy resistant arterial hypertension is an exclusion criterion of the trial. The second is the unclear situation of EPO in patients with malignant tumors. In several trials it was shown that the mortality rate of EPO-treated groups is higher than for untreated controls [39]. Therefore, a known malignancy is also an exclusion criterion of the trial.

Age, nutritional status, affected total body surface, gender, concomitant illnesses, inhalation injury or other concomitant trauma, as well as wound infections, have a large influence on the patient’s prognosis, survival rate and wound healing. Therefore we considered all of these factors carefully and discussed their relevance for our primary and secondary endpoints. As we are unable to foresee which patient group will profit most, we consider an exclusion of one of these groups as unethical.

Dermal thermal traumas are commonly seen in two age groups of adults. The first group comprises young adults aged between 18 and 28 and the second group comprises elderly persons aged over 65 years. As we are not able to foresee which of these groups would benefit most from pro-regenerative treatment, we decided to include patients aged 18 to 75 in our study [40].

The nutrition of burns patients is also a very extensively discussed topic, but so far no official guidelines exist and scientific evidence is not satisfactory. Thus we accepted the regulations of the burns centers and their in-house nutrition regimes. The authors expect that this will influence the results and they will consider this very carefully during the evaluation. This is one of the reasons why we have an adjustment for the centers (hospital).

The severity of the injury (affected total body surface and burn degree) has a significant influence on the prognosis of the patient, especially in combination with age and gender. Here again we are unable to foresee which patient group will profit most.

Concomitant illnesses are important factors especially if they interact with EPO. Thus, as stated above, we exclude patients with illnesses such as hypertension, malignant diseases, etc.

Interesting first reports concerning the prevention of burn progression by systemic administration of EPO in a rat model have been given as congress reports. These promising results need further investigation [41].

We hypothesize, therefore, that EPO can protect the epidermis, dermis and its vital structures – especially the capillaries and blood vessels – from further damage, for example, further burn progression. This very often increases the depth of the thermal injury and, therefore,
accelerates the problem. EPO has to be administered in a time frame during which its anti-apoptotic action can prevent the increase of the penumbra.

Overall, we expect EPO treatment in thermally injured patients to be safe and beneficial when combined with an adequate anti-thrombotic prophylaxis, as has already been seen for decades in patients with anemia due to renal failure.

In conclusion, we expect that because of the tissue and cell-protective effects (anti-apoptotic, anti-inflammatory, stem cell recruiting and pro-angiogenic) of EPO, its biomimetic effects will be useful in the treatment of acute thermal dermal injuries.

**Trial status**

This is an investigator-initiated Phase 2a trial funded by the German Federal Ministry of Education and Research. Full approval has been given by the ethics committees. The trial is in the recruitment phase.

**Abbreviations**

ABS: abbreviated burn severity index; AE: adverse event; BCL: B-cell lymphoma; BCL-XL: B-cell lymphoma extra-large; CD: cluster of differentiation; DSBM: data safety monitoring board; EGF: endothelial growth factor; eNOS: endothelial nitric oxide synthase; EPAS: endothelial PAS domain-containing protein; EPC: endothelial progenitor cell; EPO: erythropoietin; EPOR: EPO receptor; Hsp: heat shock protein; IGF: insulin-like growth factor; IL: interleukin; INOS: inducible nitric oxide synthase; iNOS: inducible nitric oxide synthase; JAK: janus kinase; MAPK: mitogen-activated protein kinase; MIP: macrophage inflammatory protein; PI3K-Akt: phosphatidylinositol-3 kinase (protein kinase A); rEPO: recombinant human EPO; SAH: severe adverse event; SDW: second-degree wound; SGDS: skin graft donor site; SOFA: sequential organ failure assessment; STAT: signal transducer and activator of transcription; SUSAR: suspected unexpected serious adverse reaction; TBS: total body surface; TNF: tumor necrosis factor; VEGF: vascular endothelial growth factor.

**Competing interests**

The authors declare they have no conflicting interests.

**Authors’ contributions**

CG was the vice-coordinating investigator for the trial and the main author of the article. AB was responsible for the tissue analyses of the trial, and made a substantive intellectual contribution, having developed the hypothesis together with H-GM and WJ, and performed all pre-clinical experiments. UD made a substantial intellectual contribution during the experiments. All authors read and approved the final manuscript.

**Acknowledgements**

We thank Mrs Julie Machens, Mr M. di Frangia and Mrs Dagmar Smith, medical writer, Munich, for critically revising the manuscript. Furthermore, we are indebted to the Munich Study Center (BMBF funded; grant: 01KN1104) for contributions in project management, regulatory affairs and cost calculation.

**Author details**

1. Coordinating Investigator: “EPO in Burns”, Clinic for Plastic Surgery and Hand Surgery, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Str. 22, Munich 81675, Germany. 2. Institute for Cell Techniques and Applied Stem Cell Biology, University of Leipzig, Deutscher Platz 2, Leipzig 04103, Germany. 3. Clinic for Plastic, Rekonstruktive, Hand- and Verbrennungschirurgie, Klinikum Bogenhausen, Englschalkinger Str. 77, Munich 81925, Germany. 4. Department of Plastic Surgery, Hand Surgery, Burn Center, University Hospital of the RWTH Aachen University, Pauwelstr. 30, Aachen 52074, Germany. 5. Section for Plastic Surgery and Hand Surgery, Zentrum für Schwanberbrandverletzte, Universitätsspital Klinikum Schleswig Holstein, Lübeck 23538, Germany. 6. Abteilung für Plastische, Rekonstruktive und Handchirurgie, Krankenhaus Merheim, Osmerheimer Str. 200, Köln 51109, Germany. 7. Klinik für Plastische und Handchirurgie, Brandverletztenzentrum, BG-Kliniken Bergmannstrost Halle, Halle 06112, Germany. 8. Klinik für Plastische, Wiederherstellende und Handchirurgie, Zentrum für Schwan berbrandverletzte, Klinikum Nürnberg-Bredlau, Bredlau Strasse 201, Nürnberg 90471, Germany. 9. Klinik für Hand-, Plastische, Rekonstruktive und Verbrennungschirurgie, Berufsgenossenschaftliche Unfallklinik, Tübingen 72076, Germany. 10. Klinik für Hand-, Plastische, Rekonstruktive und Verbrennungschirurgie, Berufsgenossenschaftliche Unfallklinik, Ludwigshafen 67071, Germany. 11. Institute of Medical Statistics and Epidemiology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, Munich 81675, Germany. 12. Coordination Centre for Clinical Studies, Heinrich-Heine-University, Moorenstr. 5, Düsseldorf 40225, Germany. 13. Institute for Physiology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany. 14. Münchener Studienzentrum, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, Munich 81675, Germany.

Received: 10 August 2012 Accepted: 7 March 2013

Published: 3 May 2013

**References**

1. Jellmann W: EPO after a century of research: younger than ever. Eur J Haematol 2007, 78:183–205.
2. Brines M, Cerami A: EPO-mediated tissue protection: reducing collateral damage from primary injury response. J Int Med 2008, 264:405–432.
3. Santahanam AV, D’Uscio LV, Peterson TE, Katusic ZS: Activation of endothelial nitric oxide synthase is critical for EPO-induced mobilization of progenitor cells. Peptides 2008, 29:1451–1455.
4. Bader A, Machens HG: Recombinant human EPO plays a pivotal role as a topical stem cell activator to reverse effects of damage to the skin in aging and injury. Rejuven 2010, 13:499.
5. Peterson TE, Katusic ZS: EPO testing the endothelium. Br J Pharmacol 2007, 150:823–825.
6. Sirén AL, Fratelli M, Brines M, Goermanns C, Casagrande S, Lewczuk P, Keenan S, Glieter C, Pasquali C, Capobianco A, Mannini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P: Erythropoietin prevents renal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001, 98(7):4044–4049.
7. Digiacovilou M, Lipton SA: EPO mediated neuroprotection involves crosstalk between Jak2 and NF-κB signalling cascades. Nature 2001, 412:641–647.
8. Wen TC, Sadamotyo Y, Tanaka J, Zhu PX, Nakata K, Ma YJ, Hata R, Sakanake H: EPO protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-α expression. J Neurosci Res 2002, 67:795–801.
9. Meistrell ME III, Botchkina G, Wang H, Di Santo E, Cockett KM, Bloom O, Vnishubhatk JM, Ghezzi P, Tracey KJ: Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock 1997, 8:341–348.
10. Yazhali N, Karakurt O, Atoagul H: Erythropoietin reduces lipopolysaccharide-induced cell damage and midline secretion in U937 human histiocytic lymphoma cells. Adv Ther 2008, 25:502–514.
11. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Viani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P: Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003, 198:971–975.
12. Cuzzocera S, Mazzon E, Di Padova R, Genovese T, Patel NS, Britti D, de Majo M, Caputi AP, Thiemermann C: EPO reduces the degree of arthritis.
caused by type II collagen in the mouse. *Arthritis Rheum* 2005, 52:949–950.

13. Wese L, Hempel C, Perkowka M, Kirkby N, Kurtzhalts JA: Recombinant human EPO increases survival and reduces neuronal apoptosis in a murine model of malaria. *Malar J* 2008, 7:3.

14. Strunk T, Häärit C, Temming P, Matzke N, Zimmer J, Schultz C: EPO inhibits cytokine production of neonatal and adult leukocytes. *Acta Paediatr* 2008, 97:16–20.

15. Rezaeian F, Wettstein R, Amon M, Scheuer C, Schramm R, Menger MD, Pittet B, Harder Y: EPO protects critically perfused flap tissue. *Ann Surg* 2008, 248:919–929.

16. Rezaeian F, Wettstein R, Egger JF, Sandmann F, Rücker M, Tobalem M, Vollmar B, Menger MD, Harder Y: EPO-induced upregulation of endothelial nitric oxide synthase but not vascular endothelial growth factor prevents musculocutaneous tissue from ischemic damage. *Lab Invest* 2010, 90:40.

17. Van der Meer P, Lipiec E, Henning RH, Botdeus K, van der Velden J, Voors AA, van Veldhusen DJ, van Gilst WH, Schoemaker RG: EPO induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. *Am J Cardiol* 2005, 96:125–133.

18. Bunn HF, Huang LE, Park JW, Zhu H: EPO: a model system for studying oxygen-dependent gene regulation. *J Exp Biol* 1998, 201:1197–1201.

19. Chavez JC, Baranova O, Lin J, Pichulé P: The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of EPO in cortical astrocytes. *J Neurosci* 2006, 26:9047–9081.

20. Silva M, Benito A, Sanz C: EPO can induce the expression of Bcl-XL through Stat 5 in EPO-dependent progenitor cell lines. *J Biol Chem* 1999, 274:22165–22169.

21. Kim I, Kim CH, Yim YS: Autocrine function of EPO in IGF-1-induced EPO biosynthesis. *Neuroreport* 2008, 19:1699–1703.

22. Sharples EJ, Patel N, Brown P: Erythropoietin protects kidneys against the injury and dysfunction caused by ischemia-reperfusion. *J Am Soc Nephrol* 2004, 15:2116–2124.

23. Silva M, Grillt D, Benito A: EPO can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. *Blood* 1996, 88(5):1576–1582.

24. Lui JC, Kong SK: Heat shock protein 70 inhibits the nuclear import of apoptosis-inducing factor to avoid DNA fragmentation in TF-1 cells during erythropoiesis. *FEBS Lett* 2007, 581:109–117. Supplement.

25. Schultz C, Zimmer J, Häärit C, Rupp J, Temming P, Strunk T: Attenuation of monocyte proinflammatory cytokine responses to *Neisseria meningitidis* in children by erythropoietin. *Clin Exp Immunol* 2008, 154:187–191.

26. Bodd E, Komminga A, Funk W, Laugsch M, Duske U, Jeffknn W, Prays R: Human hair follicles are an extrarenal source and a nonhematopoietic target of EPO. *FASEB J* 2007, 21:3346–3354.

27. Bader A, Ebert S, Giri S, Kremer M, Liu S, Nerlich A, Günter C, Smith DU, Machens HG: Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO. *Int J Nanomed* 2013, 8:1127–1237.

28. Gakano M, Atavilla D, Cucinotta D, Russo GT, Calo M, Bitto A, Marini H, Marin R, Adamo EB, Seminara P, Minutoli L, Torre V, Squadrato F: Recombinant human EPO stimulates angiogenesis and wound healing in the genetically diabetic mouse. *Diabetes* 2004, 53:2509.

29. Haroon ZA, Amin K, Jiang X, Arcasoy MO: A novel role of EPO during fibrin-induced wound-healing response. *Am J Pathol* 2003, 163(3):993–1000.

30. Rasmussen P, Nordborg N, Taudorf S, Sorensen H, Berg RM, Jakobs RA, Bailey OM, Olsen NV, Secher NH, Moller K, Lundby C: Brain and skin do not contribute to the systemic rise in EPO during acute hypoxia in humans. *FASEB J* 2012, 26(5):1831–1834.

31. Sorg H, Krueger C, Schulte T, Menger MD, Schmitt F, Vollmar B: Effects of EPO in skin wound healing are dose related. *FASEB J* 2009, 23:1–10.

32. Gakano M, Atavilla D, Bitto A, Minutilo L, Calo M, La Cascio P, Polito F, Giugliano G, Squadrato G, Mioni C, Giuliani D, Venuti FS, Squadrato F: Recombinant human EPO improves angiogenesis and wound healing in experimental burn wounds. *Crit Care Med* 2006, 34:1139–1146.

33. Brückner UB, Brockmeyer NH, Gödicke P: Einbeziehung von volljährigen einwilligungsfähigen Notfallpatienten. Deutsche ÄrzteblattA1–A7.

34. Jellkman W: Molecular biology of EPO. *Intern Med* 2004, 43:649–659.

35. Still JM Jr, Belcher K, Law EJ, Thompson W, Jordan M, Lewis M, Saffle J, Hunt J, Purdue GF, Waymac J: A double-blind prospective evaluation of recombinant human erythropoietin in acutely burned patients. *J Trauma* 1995, 38(2):233–236.

36. Fleming RF, Herdon DN, Vaidya S, Nichols R, Desai MH, Rutan RL, Waymack JP: The effect of erythropoietin in normal healthy volunteers and pediatric patients with burn injuries. *Surgery* 1992, 112(2):424.

37. Zhou YH, Luo CJ, Guo ZH, Kong PY, Zhu ZM: The effects of burns serum on the erythropoiesis and granulopoiesis in bone marrow in mice. *Zhonghua Shao Shang Za Zhi* 2005, 21:177–180.

38. Conwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klauser MA, Conwin MJ: EPO critical care trials group: Efficacy and safety of epoetin alfa in critically ill patients. *N Engl J Med* 2007, 357(10):965–976.

39. Roche Pharma AG: Fachinformation 2011. *Neorecombin Multidose* 50,000 IE. Grenzach-Wyhlen, Germany.

40. De Roche R: Epidemiologie in Bruck, Müller, Stern. *Handbuch der Verbrennungstherapie*. 2002 ECOMED. ISSN 3-600-51800-6.

41. Rezaeian F, Wettstein R, Harder Y: Secondary burn progression prevented by EPO: a matter of dosage and timing. In *Kongress der Deutschen Gesellschaft für Chirurgie*. Munich; 2011:128.

**Cite this article as:** Günter et al.: A multi-center study on the regenerative effects of erythropoietin in burn and scalding injuries: study protocol for a randomized controlled trial. *Trials* 2013 14:124.